Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Assets Average (2021 - 2025)

Vivos Therapeutics' Assets Average history spans 5 years, with the latest figure at $25.4 million for Q4 2025.

  • Quarterly results put Assets Average at $25.4 million for Q4 2025, up 65.83% from a year ago — trailing twelve months through Dec 2025 was $25.4 million (up 65.83% YoY), and the annual figure for FY2025 was $20.2 million, up 55.44%.
  • Assets Average for Q4 2025 was $25.4 million at Vivos Therapeutics, down from $25.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $43.6 million in Q3 2021 to a low of $10.5 million in Q4 2023.
  • The 5-year median for Assets Average is $17.4 million (2022), against an average of $21.4 million.
  • The sharpest move saw Assets Average crashed 57.01% in 2022, then surged 65.83% in 2025.
  • Year by year, Assets Average stood at $37.4 million in 2021, then plummeted by 57.01% to $16.1 million in 2022, then crashed by 34.47% to $10.5 million in 2023, then surged by 45.54% to $15.3 million in 2024, then surged by 65.83% to $25.4 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $25.4 million, $25.8 million, and $18.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.